Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Medicare Part D Cost Trends: A Good News/Bad News Story For Biopharma

Executive Summary

Despite headlines about soaring drug costs, Medicare Part D beneficiaries are not seeing much if any increase in their out-of-pocket spending. But that doesn’t necessarily mean that costs of the program are stable – which could open up a new area for policy activity in 2017 and beyond.


Related Content

Medicare Part D Catastrophic Spending Surge Needs Solutions, OIG Says
Paying For Cures Requires Bigger Budgets, Not Lower Drug Prices – Execs
Part D Reform Proposals From MedPAC May Find Traction After Election
Thinking Outside The Box On Rx Pricing: From Vaccines To Part D Bundling
Drug-Pricing Help Wanted: Wyden, Grassley Seek Public Input On Policy Ideas